Swiss National Bank Has $47.31 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Swiss National Bank reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 656,240 shares of the medical equipment provider's stock after selling 36,500 shares during the quarter. Swiss National Bank owned 0.29% of Hologic worth $47,308,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in HOLX. FMR LLC boosted its holdings in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Hologic during the 4th quarter worth approximately $27,007,000. Swedbank AB lifted its position in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after buying an additional 306,562 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock worth $110,700,000 after buying an additional 238,222 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HOLX shares. Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price for the company. Raymond James reaffirmed an "outperform" rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Wolfe Research initiated coverage on Hologic in a research note on Friday, December 13th. They set a "peer perform" rating for the company. BNP Paribas raised Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Stephens reissued an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Stock Down 0.7 %

Shares of NASDAQ:HOLX traded down $0.46 during midday trading on Thursday, hitting $61.01. The stock had a trading volume of 3,109,158 shares, compared to its average volume of 1,722,375. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business's 50-day simple moving average is $66.50 and its 200-day simple moving average is $74.28. The company has a market cap of $13.69 billion, a P/E ratio of 19.25, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.